Beth Devin
Scout, Investor & Advisor @ HearstLab
San Francisco Bay Area, United States
Beth Devin is a Series A investor at HearstLab in San Francisco Bay Area focused on B2B and PaaS. Beth Devin is the managing director and head of Innovation Network & Emerging Technology at Citi Ventures.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Beth Devin invests in
Stages Beth Devin invests in
Countries Beth Devin invests in
Investment Focus
Industry
- B2B 1 (100%)
- PaaS 1 (100%)
- SaaS 1 (100%)
- Software 1 (100%)
- Pharmaceutical 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Strategikon Pharma
|
Clinical Maestro™ by Strategikon Pharma is the only commercially available software platform for the end- to- end management of “clinical business operations”, which is the pharmaceutical industry vertical for planning, outsourcing and budgeting clinical trials. Biopharmaceutical companies outsource 90% of their clinical development pipelinespending billions of dollars engaging in highly complex outsourced relationships with thousands of global service providers, each using their own processes, systems and reporting structures. These sophisticated relationships require complex outsourcing strategies, demanding clinical financial planning, extensive sourcing due diligence and rigorous performance management. Currently the industry manages these activities in Excel, using labor intensive, inefficient processes, costing billions of dollars in infrastructure costs, regulatory non-compliance fines and delays to market. Clinical Maestro takes a radically different approach to the management of clinical portfolio through a transformative redesign of Excel-driven processes into end-to-end integrated workflows, breaking the communication and data integration siloes between pharma companies and their outsourcing partners. Clinical Maestro™ cases studies with leading pharmaceutical companies and CROs demonstrate savings of >80% vs. manual processes, >95% prediction accuracy for clinical study budgets and high user satisfaction and engagement. | $7M / Series A / Feb 06, 2024 |
Co-Investors
About HearstLab
HearstLab is an early-stage venture fund focused on women-led startups innovating across the enterprise technology, data analytics, health, fintech, transportation and media spaces. To date, HearstLab has invested in over 56 companies at the Seed and Series A stages, with four successful exits. The firm often participates as a co-investor and infollow-on rounds. HearstLab is a venture arm of the Hearst Corporation ("Hearst") and provides one year of services in addition to cash investments. With access to Hearst's resources across 360+ businesses, HearstLab’s breadth of services includes providing assistance with commercial deals, privacy and security, legal services, marketing support and raising capital. Portfolio companies also benefit from the strategic guidance and resource support of HearstLab Scouts, women leaders across Hearst who share their networks and expertise. HearstLab has a full-time dedicated team assisting with UI/UX, DevOps engineering, data security, data science, brand storytelling, financial modeling and business development.
HearstLab Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Eve Burton
Co-Founder
|
|||
Lisa Burton
Vice President
|
|||
Azahara Espejo
Director
|
|||
|
Beth Devin
Scout, Investor & Advisor
|
|||
Chris Wilkes
Vice President
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Beth Devin invest in?
Beth Devin invests primarily in B2B, PaaS and SaaS startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Beth Devin last invest?
The most recent investment recorded for Beth Devin closed in Feb 2024. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
